Avitar Enters Rapidly Expanding Oral Fluid-Based Laboratory Drug Testing Market

Avitar Continues Track Record of Innovation and Improves Company's Ability to Compete in $1.5B Drug Testing Market

Canton, MA - Avitar, Inc., developer of the world's first oral fluid-based, on-site screen for drugs-of-abuse, announced ORALscreenLAB, a comprehensive array of laboratory-based oral fluid drug screens. With the addition of ORALscreenLAB, Avitar now offers the industry's widest selection of oral fluid-based solutions to combat drug abuse.

"Our goal is to provide employers with all the necessary tools to significantly reduce the incidences of drug abuse on the job," said Peter Phildius, Chairman and CEO of Avitar. "Industry experts recognize that random drug screening is an extremely effective deterrent to drug abuse, however, traditional urine testing is not well suited for random screening in the corporate sector. Oral fluid-based testing is an enabling technology that provides corporations with a key component in establishing an effective drug- free workplace program."

Phildius explained, "Oral fluid-based technology removes the barriers to random testing associated with urine. For example, urine drug testing presents gender issues, problems with sample substitution or adulteration (beating the test), and a general lack of social acceptance and convenience. Observed, on-site, oral fluid collection also eliminates the costly employee downtime associated with specialized urine collection facilities. With the addition of ORALscreenLAB to our comprehensive group of drug tests and consulting services, Avitar is becoming a single source company for oral fluid-based drug free workplace solutions."

In practice, oral fluid-based testing for drugs-of-abuse has proven to be most efficient for organizations looking to reduce workplace drug use. Research shows that oral fluid testing yields results that are comparable in accuracy to urine tests, and can detect the presence of virtually all drugs within minutes of consumption. Avitar will continue to focus its marketing and sales efforts on its on-site ORALscreen DRUGOMETER. ORALscreenLAB, however, presents a viable option to corporations wishing to step away from urine testing, but are not yet ready to implement on-site testing technology.

SOURCE: Avitar, Inc.